Full Name
Wee Joo Chng
Variants
Chng W.J
Chng, W.J.
Chng W.-J.
Wee Joo Chng
Chng, W.-J.
 
 
 
Email
mdccwj@nus.edu.sg
 
 

Publications

Refined By:
Date Issued:  [2000 TO 2021]

Results 1-20 of 129 (Search time: 0.011 seconds).

Issue DateTitleAuthor(s)
13-Sep-2021A phase 2 study of carfilzomib, cyclophosphamide and dexamethasone as frontline treatment for transplant-eligible MM with high-risk features (SGH-MM1)Chen, Yunxin ; Gopalakrishnan, Sathish Kumar; Ooi, Melissa ; Sultana, Rehena ; Lim, Li Hui; Grigoropoulos, Nicholas ; Ong, Shin Yeu ; Xu, Mingge; Chng, Wee Joo ; Goh, Yeow Tee ; Nagarajan, Chandramouli
21-Jun-2021A unique rhinologic manifestation of multiple myelomaSeah, Jun Jie; Chng, Wee Joo ; Thong, Mark Kim Thye
320-Sep-2018Aberrant hyperediting of the myeloma transcriptome by ADAR1 confers oncogenicity and is a marker of poor prognosisTeoh, Phaik Ju ; An, Omer ; Chung, Tae-Hoon ; Chooi, Jing Yuan ; Toh, Sabrina HM ; Fan, Shuangyi ; Wang, Wilson ; Koh, Bryan TH; Fullwood, Melissa J ; Ooi, Melissa G ; de Mel, Sanjay; Soekojo, Cinnie Y; Chen, Leilei ; Ng, Siok Bian ; Yang, Henry ; Chng, Wee Joo 
42015Aberrant nuclear factor-kappa B activity in acute myeloid Leukemia: From molecular pathogenesis to therapeutic targetZhou J. ; Ching Y.Q. ; Chng W.-J. 
51-Mar-2011Activated oncogenic pathways and therapeutic targets in extranodal nasal-type NK/T cell lymphoma revealed by gene expression profilingNg, Siok-Bian ; Selvarajan, Viknesvaran; Huang, Gaofeng; Zhou, Jianbiao ; Feldman, Andrew L; Law, Mark; Kwong, Yok-Lam; Shimizu, Norio; Kagami, Yoshitoyo; Aozasa, Katsuyuki; Salto-Tellez, Manuel; Chng, Wee-Joo 
628-Apr-2014Allogeneic haematopoietic SCT for natural killer/T-cell lymphoma: a multicentre analysis from the Asia Lymphoma Study GroupTse, E.; Chan, T.S.Y.; Koh, L.-P.; Chng, W.-J. ; Kim, W.-S.; Tang, T.; Lim, S.-T.; Lie, A.K.W.; Kwong, Y.-L.
723-Feb-2021Application of Advanced Mass Spectrometry-Based Proteomics to Study Hypoxia Driven Cancer ProgressionVinaiphat, Arada; Low, Jee Keem; Yeoh, Kheng Wei ; Chng, Wee Joo ; Sze, Siu Kwan
827-Jan-2020Application of an ex-vivo drug sensitivity platform towards achieving complete remission in a refractory T-cell lymphomade Mel, S.; Rashid, M.B.M.; Zhang, X.Y.; Goh, J.; Lee, C.T.; Poon, L.M.; Chan, E.H.L. ; Liu, X.; Chng, W.J. ; Chee, Y.L.; Lee, J.; Yuen, Y.C.; Lim, J.Q. ; Chia, B.K.H.; Laurensia, Y.; Huang, D.C.; Pang, W.L.; Cheah, D.M.Z.; Wong, E.K.Y.; Ong, C.K. ; Tang, T. ; Lim, S.T. ; Ng, S.B. ; Tan, S.Y. ; Loi, H.-Y. ; Tan, L.K. ; Chow, E.K. ; Jeyasekharan, A.D. 
91-Sep-2020ASLAN003, a potent dihydroorotate dehydrogenase inhibitor for differentiation of acute myeloid leukemia.Zhou, Jianbiao ; Yiying Quah, Jessie ; Ng, Yvonne ; Chooi, Jing-Yuan ; Hui-Min Toh, Sabrina ; Lin, Baohong; Zea Tan, Tuan ; Hosoi, Hiroki ; Osato, Motomi ; Seet, Qihui; Ooi, Lisa AG; Lindmark, Bertil; McHale, Mark; Chng, Wee-Joo 
1028-Mar-2013ATM-dependent spontaneous regression of early Eμ-myc-induced murine B-cell leukemia depends on natural killer and T cells.Croxford, J.L. ; Tang, M.L.; Pan, M.F. ; Huang, C.W.; Kamran, N.; Phua, C.M.; Chng, W.J. ; Ng, S.B. ; Raulet, D.H.; Gasser, S. 
11Jul-2017Belinostat exerts antitumor cytotoxicity through the ubiquitin-proteasome pathway in lung squamous cell carcinomaKong, L.R ; Tan, T.Z ; Ong, W.R; Bi, C; Huynh, H ; Lee, S.C ; Chng, W.J ; Eichhorn, P.J.A ; Goh, B.C 
121-Jan-2016Bortezomib-related neuropathy may mask CNS relapse in multiple myeloma: A call for diligenceAbid, Muhammad Bilal; De Mel, Sanjay; Abid, Muhammad Abbas; Tan, Kong Bing; Chng, Wee Joo 
1329-Apr-2021CAR T-cell therapy in multiple myeloma: more room for improvementTeoh, Phaik Ju ; Chng, Wee Joo 
1417-Mar-2017Carfilzomib and Dexamethasone vs Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma: Results of the Phase 3 Study ENDEAVOR (NCT01568866) According to Age SubgroupHeinz Ludwig; Meletios A. Dimopoulos; Philippe Moreau; Wee Joo Chng ; Hartmut Goldschmidt; Roman Hajek; Thierry Facon; Ludek Pour; Ruben Niesvizky; Albert Oriol; Laura Rosinol; Aleksandr Suvorov; Gianluca Gaidano; Tomas Pika; Katja Weisel; Vesselina Goranova-Marinova; Antonio Palumbo; Heidi Gillenwater; Nehal Mohamed; Sanjay Aggarwal; Shibao Feng; Douglas Joshua
151-Jun-2017Carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study ENDEAVORChng, W-J ; Goldschmidt, H; Dimopoulos, MA; Moreau, P; Joshua, D; Palumbo, A; Facon, T; Ludwig, H; Pour, L; Niesvizky, R; Oriol, A; Rosinol, L; Suvorov, A; Gaidano, G; Pika, T; Weisel, K; Goranova-Marinova, V; Gillenwater, HH; Mohamed, N; Feng, S; Aggarwal, S; Hajek, R
1622-Sep-2017Carfilzomib-Dexamethasone vs Subcutaneous or Intravenous Bortezomib in Relapsed or Refractory Multiple Myeloma: Secondary Analysis of Phase 3 ENDEAVOR StudyHartmut Goldschmidt; Philippe Moreau; Heinz Ludwig; Ruben Niesvizky; Wee Joo Chng ; Douglas Joshua; Katja Weisel; Andrew Spencer; Robert Orlowski; Shibao Feng; Karim Iskander; Meletios A. Dimopoulos
17Oct-2009Centrosomes and myeloma; aneuploidy and proliferationChng, W.J. ; Fonseca, R.
1816-Aug-2021Chromatin interaction neural network (ChINN): a machine learning-based method for predicting chromatin interactions from DNA sequencesCao, Fan ; Zhang, Yu; Cai, Yichao; Animesh, Sambhavi; Zhang, Ying; Akincilar, Semih Can; Loh, Yan Ping; Li, Xinya; Chng, Wee Joo ; Tergaonkar, Vinay ; Kwoh, Chee Keong; Fullwood, Melissa J 
192008Clinical and biological significance of RAS mutations in multiple myelomaChng, W.J. ; Van, Wier S.; Fonseca, R.; Gonzalez-Paz, N.; Price-Troska, T.; Rajkumar, S.V.; Kyle, R.A.; Henderson, K.J.; Greipp, P.; Jacobus, S.; Oken, M.M.; Van, Ness B.
2020-Oct-2020Clinical features and survival outcomes in IgD myeloma: a study by Asia Myeloma Network (AMN)Liu, Jin; Hu, Xiaoxia; Jia, Yanchun; Lu, Jin; Lee, Jae Hoon; Kim, Kihyun; Chen, Wenming; Liu, Aijun; Liu, Yang; Chen, Q; Zhang, Chunyang; Suh, Cheolwon; Kim, Min Kyoung; Zhou, Fan; Chng, Wee Joo ; Kumar, Shaji K; Durie, Brian; Hou, Jian; Fu, Weijun; Du, Juan